Limp

New collaboration between Boehringer Ingelheim and Sleip leverages AI-technology to help detect lameness in horses

Retrieved on: 
Monday, February 19, 2024

A new global commercial partnership between Boehringer Ingelheim and Sleip will expand access to AI to enhance detection, diagnosis and treatment of lameness in horses.

Key Points: 
  • A new global commercial partnership between Boehringer Ingelheim and Sleip will expand access to AI to enhance detection, diagnosis and treatment of lameness in horses.
  • This partnership delivers on the shared commitment of Boehringer and Sleip to deliver innovative solutions that help veterinary professionals continue to advance their profession and improve the care and wellbeing of horses.
  • Changes in gait and signs of lameness can be less pronounced at first and difficult to detect.
  • Through this collaboration, Boehringer will support the introduction of the pioneering Sleip app to the veterinary community, making this technology even more accessible.

PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Feline Tolerance to Intra-articular Injections of Spryng™ with OsteoCushion™ Technolgoy

Retrieved on: 
Wednesday, February 7, 2024

Spryng™ with OsteoCushion™ Technology) into the joints of cats.

Key Points: 
  • Spryng™ with OsteoCushion™ Technology) into the joints of cats.
  • The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
  • Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
  • The data provided demonstrated the excellent safety profile of Spryng when injected IA into 40 joints (10 each, shoulder, hip, elbow, stifle) across 10 individual cats.

PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Canine Tolerance to Intra-articular Injections of Spryng™ with OsteoCushion™ Technology

Retrieved on: 
Wednesday, January 31, 2024

Spryng™ with OsteoCushion™ Technology) into the joints of dogs.

Key Points: 
  • Spryng™ with OsteoCushion™ Technology) into the joints of dogs.
  • The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
  • Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
  • To view the Technical Bulleton discussing the tolerability study involving the intra-articular injection of Spryng in the joints of dogs, please visit the following:

New to The Street Re-signs PetVivo Holdings, Inc. for another 12-Month TV Media Series; Agreement Includes Commercials and Billboard Ads

Retrieved on: 
Wednesday, December 20, 2023

The agreement calls for the continuation of filming and broadcasting tailored interviews and commercials and streaming digital billboard aids throughout key locations in New York City.

Key Points: 
  • The agreement calls for the continuation of filming and broadcasting tailored interviews and commercials and streaming digital billboard aids throughout key locations in New York City.
  • Spryng™ is an intra-articular injectable veterinary medical device composed of a naturally derived matrix of building proteins that mimic collagen tissue.
  • "Bloomberg Originals" streams on several platforms and airs during primetime and weekend slots on Bloomberg TV, BTV+, and Bloomberg.com.
  • Vince Caruso, CEO / Producer of New to The Street, states, "I am excited about having PETV on the show for another 12-part media series.

PetVivo Holdings, Inc. Achieves National Distribution of Spryng™ to More than 600 Veterinary Clinics in 49 States

Retrieved on: 
Monday, December 11, 2023

This advance was demonstrated by the increase of veterinarian inquiries and podium speaker references related to Spryng at the American Association of Equine Practitioners (“AAEP”) conference over the past three years.

Key Points: 
  • This advance was demonstrated by the increase of veterinarian inquiries and podium speaker references related to Spryng at the American Association of Equine Practitioners (“AAEP”) conference over the past three years.
  • SPRYNG™ with OsteoCushion™ Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles.
  • Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of lameness and other joint-related afflictions, such as osteoarthritis.
  • “We are also seeing enthusiasm surrounding Spryng in the veterinary community with veterinarians sending us videos and images touting the benefits of Spryng,” said Mr. Lai.

PetVivo Holdings, Inc. to Exhibit at American Association of Equine Practitioners Conference in San Diego, California

Retrieved on: 
Tuesday, November 21, 2023

PetVivo will exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology, a medical device injection of sterilized, extra-cellular matrix microparticles that are lubricious and spongy used in the treatment of lameness and other joint related afflictions, such as osteoarthritis.

Key Points: 
  • PetVivo will exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology, a medical device injection of sterilized, extra-cellular matrix microparticles that are lubricious and spongy used in the treatment of lameness and other joint related afflictions, such as osteoarthritis.
  • The AAEP is the largest veterinary equine conference that services the United States, and normally plays host to more than 5,000 participants including many of the top industry professionals.
  • If you would like to attend the presentations by Dr. Yarbrough and Dr. Manning the details are provided below.
  • Location: San Diego Convention Center in San Diego, California
    For more information about PetVivo Holdings, Inc. and its innovative product, Spryng, please contact [email protected] or visit https://petvivo.com/ and https://sprynghealth.com/ .

PetVivo Reports Second Quarter of Fiscal 2024 Financial Results

Retrieved on: 
Tuesday, November 14, 2023

EDINA, MN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended September 30, 2023 (“second quarter of 2024”).

Key Points: 
  • Conference call begins at 4:00 p.m. Central time today
    EDINA, MN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended September 30, 2023 (“second quarter of 2024”).
  • Revenues were $207,366 and $223,280 for three months ended September 30, 2023 and 2022, respectively.
  • Cost of sales was $140,913 and $148,149 for the three months ended September 30, 2023 and 2022, respectively.
  • The weighted average number of shares outstanding was 12,325,973 and 10,021,090 for the six months ended September 30, 2023 and 2022, respectively.

PetVivo Holdings, Inc. Announces Scheduled Presentations by PetVivo Veterinarians at the American Association of Equine Practitioners Convention in San Diego, California

Retrieved on: 
Thursday, November 2, 2023

Tom Yarbrough, DVM, ACVS, the Director of Product Research for PetVivo Holdings Inc., is providing a presentation entitled “Modern Wild West: Navigating the new classes of joint therapeutics”.

Key Points: 
  • Tom Yarbrough, DVM, ACVS, the Director of Product Research for PetVivo Holdings Inc., is providing a presentation entitled “Modern Wild West: Navigating the new classes of joint therapeutics”.
  • In addition, Joseph Manning, DVM, MBA, Senior Technical Veterinarian for PetVivo Holdings, inc., will be discussing the use of Spryng™ with OsteoCushion™ Technology in a presentation entitled “Advancements in Intra-Articular Therapies: Experiences with a novel collagen-elastin hydrogel microparticles (CEHM) biomaterial used intra-articularly for joint conditions in equines”.
  • If you would like to attend the presentations by Dr. Yarbrough and Dr. Manning the details are provided below.
  • PetVivo’s innovative product, SPRYNG™ with OsteoCushion™ Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles; Spryng microparticles perform in the joint as wet, slippery micro-cushions used in the management of lameness and other joint related afflictions, such as osteoarthritis.

PetVivo Holdings, Inc. Encouraged Over Positive Response Received at 2023 American College of Veterinary Surgeons Conference

Retrieved on: 
Wednesday, October 25, 2023

Two presentations at the ACVS Conference heightened the enthusiastic interest in veterinarians to learn more about Spryng and consider its use in their practices.

Key Points: 
  • Two presentations at the ACVS Conference heightened the enthusiastic interest in veterinarians to learn more about Spryng and consider its use in their practices.
  • Spryng™ with OsteoCushion™ Technology) into the stifle joint of dogs with suspected cruciate ligament rupture.
  • Dr. Erik Kleeman, DVM presented the clinical study poster at the ACVS Conference.
  • In summary, this study demonstrated that Spryng™ is a reasonable, non-invasive alternative for patients with cranial cruciate disease (“CCD”) when patient and/or owner factors preclude surgical intervention.

PetVivo Holdings, Inc. Announces Presentation of Clinical Study Results at the American College of Veterinary Surgeons Conference in Louisville, Kentucky

Retrieved on: 
Thursday, October 12, 2023

Spryng™ with OsteoCushion™ Technology) into the stifle joint of dogs with suspected cruciate ligament rupture.

Key Points: 
  • Spryng™ with OsteoCushion™ Technology) into the stifle joint of dogs with suspected cruciate ligament rupture.
  • Dr. Erik Kleeman, DVM will be presenting the poster at ACVS.
  • There were significant improvements in all of the primary and secondary clinical variables throughout the study period (pain, lameness, quality of life scoring).
  • To view the poster presentation and a video interview of Dr. Kleeman discussing the clinical study presented at the ACVS annual conference please visit the following: